-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Bronchoscopic Ablation: A Small Step for Heat Therapy, a Giant Leap for Lung Cancer
Surgery has long been the gold standard for diagnosis and management of early-stage operable lung cancer. For patients with inoperable disease or more extensive disease, however, alternative approaches are emerging. For example, there are ample data to support stereotactic body radiation therapy as an alternative treatment.1 Percutaneous ablation, however, despite being available for 2 decades, is…
-
Prof. Fabrice Barlesi Appointed Chief Executive Officer of Gustave Roussy for a Term of 5 years
Prof. Fabrice Barlesi has been appointed as chief executive officer of Gustave Roussy for a term of 5 years. Prof. Barlesi has been medical director and clinical research director there since January of 2020. Prior to that Prof. Barlesi was professor of medicine at the University of Aix-Marseille and was the head of the Multidisciplinary…
-
David R. Gandara, MD, Appointed Chief Medical Officer (CMO) of the International Society for Liquid Biopsy (ISLB)
David R. Gandara, MD, has been appointed chief medical officer (CMO) of the International Society for liquid biopsy (ISLB), an international nonprofit organization dedicated to advancing the field of liquid biopsy in cancer diagnosis and management. In addition to being a previous IASLC President (2009-2011), Treasurer (2017), and World Conference President (2009), Dr. Gandara is…
-
The IASLC Supports International Day for Clean Air for Blue Skies “Healthy Air, Healthy Planet” Campaign
The International Association for the Study of Lung Cancer (IASLC)—as an international organization of lung cancer experts who serves patients in both developed and developing countries, as well as vulnerable populations living in heavily polluted areas—is committed to increasing global awareness about the dangers of air pollution. As part of the IASLC’s efforts to work…
-
Narjust Duma Moves to Dana-Farber Cancer Institute
Narjust Duma, MD, has been named associate director of the Cancer Care Equity Program and assistant professor of medicine at Dana-Farber Cancer Institute/Harvard Medical School. She will develop strategies to diminish health care disparities and enhance cancer care delivery while continuing her practice as a thoracic oncologist as well as her research, both of which…
-
Gemcitabine: A New Chemotherapy Partner for Immune Checkpoint Inhibitors? Insights From the ORIENT-12 Study
Squamous cell lung cancer (SqCLC), which accounts for approximately 25% to 30% of all lung cancer cases, is the second-most prevalent histologic subtype of NSCLC. Its distinct clinicopathologic and molecular characteristics present obstacles to the development of treatments for SqCLC, resulting in a poorer prognosis. It affects patients who are older, who have more comorbidities…
-
Peter Bach, MD, is the New Chief Medical Officer at Delfi Diagnostic
Peter Bach, MD, is the new chief medical officer at Delfi Diagnostics, a developer of blood tests for early detection of multiple types of cancer. Dr. Bach leaves Memorial Sloan Kettering after 23 years, where he served as director of the Center for Health Policy and Outcomes. “Lung cancer screening is the ideal place to…
-
Joshua Bauml, MD, moves to The Janssen Pharmaceutical Companies of Johnson & Johnson
Joshua Bauml, MD, has moved to The Janssen Pharmaceutical Companies of Johnson & Johnson from the University of Pennsylvania. Dr. Bauml was with the University of Pennsylvania for a decade—2 years as a fellow and 8 years as faculty—most recently servicing as an Assistant Professor of Medicine. Dr. Bauml will be joining the lung cancer…
-
Jean-Charles Soria, MD, PhD Joins Amgen
Jean-Charles Soria, MD, PhD, joined Amgen in early August 2021 as senior vice president of the oncology therapeutic sector. Prof. Soria, previously served as senior vice president of Research & Development in Oncology at AstraZeneca, where he was responsible for strategy and development of new immuno-oncology, cell therapy, and conjugated antibody agents. Most recently Dr.…
-
Suresh S. Ramalingam, MD, Appointed Executive Director of the Winship Cancer Institute and Associate Vice-President for Cancer at the Woodruff Health Sciences Center of Emory University
Suresh S. Ramalingam, MD, was appointed as the executive director of the Winship Cancer Institute and Associate Vice-President for Cancer at the Woodruff Health Sciences Center of Emory University on July 01, 2021. Previously he served as the deputy director of Winship Cancer Institute. Dr. Ramalingam is also the Roberto D. Goizueta distinguished chair for…